Determination of a Novel Aurora-A (aura) Kinase AKI603 by UPLC-MS/MS and Its Application to a Bioavailability Study in Rat

Zhenzhen Zhao,Lingjie Huang,Xiaoli Gou,Zhangwei Li,Jiangying Chen,Dingsheng Wen,Fulin Jiang,Gui Lu,Huichang Bi,Min Huang,Guoping Zhong
DOI: https://doi.org/10.1016/j.jpba.2016.03.041
IF: 3.571
2016-01-01
Journal of Pharmaceutical and Biomedical Analysis
Abstract:A simple, sensitive and accurate ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the determination of AKI603 in rat plasma has been firstly developed and validated. After a simple liquid-liquid extraction (LLE) with ethyl acetate, the analytes were separated on C18 column (2.1 x 100 mm, 1.9 mu m, Thermo) by gradient elution with mobile phase of water (A) (containing 5 mM ammonium acetate and 0.1% formic acid) and methanol (B) with a flow rate of 0.3 mL min(-1) and then analyzed by mass spectrometry in the positive multiple reactions monitoring (MRM) mode. The mass transitions monitored were miz 410.0 -> 352.9, m/z 457.1 -> 367.9 for AKI603 and internal standard (Ly-7z), respectively. The developed method was validated for specificity, linearity and lower limit of quantification, intra- and inter-day precision and accuracy, extraction recovery, matrix effect and stability whose values satisfied the acceptable limits. The calibration curves for AKI603 was linear in concentration ranges of 0.025-5000 ng mL(-1). The method has been successfully used to the bioavailability study of AKI603 administered to rats intravenously (2.5 mg/kg) or orally (25 mg/kg). The oral bioavailability of AKI603 in rats was calculated as 28.7 +/- 9.7%. (C) 2016 Elsevier B.V. All rights reserved.
What problem does this paper attempt to address?